Summary
Full summaryExecutive Assessment
Revenue increased 32% to $45.0B, driven by Mounjaro, Zepbound, and Verzenio; net income doubled to $10.6B.
- Revenue rose 32% YoY to $45.0B, with U.S. revenue up 39% and outside U.S. up 19%.
- Net income increased 102% to $10.6B, and diluted EPS rose 102% to $11.71.
- Gross margin expanded 2.1 percentage points to 81.3%, driven by favorable product mix and higher realized prices.
- Mounjaro, Zepbound, and Verzenio were primary growth drivers, while Trulicity declined 26% due to competitive dynamics and supply constraints.
Financial Highlights
| Metric | Current Period | Prior Period | Change | Investor Takeaway |
|---|---|---|---|---|
Revenue | $45.0B | $34.1B | +32.0% | Driven by volume growth and higher realized prices, particularly from Mounjaro, Zepbound, and Verzenio. |
Net Income | $10.6B | $5.2B | +103.8% | Increase primarily due to higher gross margin, partially offset by higher R&D and SG&A expenses. |
Diluted EPS | $11.7 | $5.8 | +101.9% | Growth aligned with net income; share count remained relatively stable. |
Gross Margin | 81.3% | 79.2% | +2.1 ppts | Favorable product mix and higher realized prices. |
Operating Cash Flow | $8.8B | $4.2B | +109.5% | Reflects higher net income and working capital changes. |
Total Assets | $78.7B | $64.0B | +23.0% | Increase driven by higher cash, receivables, inventories, and property/equipment. |
Total Debt | $33.6B | $25.2B | +33.3% | Increase due to long-term debt issuances to fund business development and capital investments. |
Profitability
- Net margin expanded to 23.5% from 15.4%, driven by operating leverage and gross margin improvement.
- R&D expenses rose 18% to $11.0B, reflecting continued investment in early and late-stage pipeline.
- Acquired IPR&D charges were $3.3B (vs. $3.8B in 2023), primarily from the Morphic acquisition.
Cash flow
- Free cash flow (operating cash flow less capex) was $3.8B, up from $0.8B in 2023, as operating cash flow growth outpaced capex increase.
- Investing cash outflows of $9.3B included $5.1B in capex and $3.3B for acquired IPR&D.
- Financing cash inflows of $1.2B reflected $11.4B in long-term debt issuances, offset by $4.7B in dividends and $2.5B in share repurchases.
Balance sheet
- Cash and equivalents rose to $3.3B from $2.8B.
- Working capital turned positive at $4.4B (current ratio 1.15x) from -$1.6B (0.94x) in 2023, driven by higher current assets.
- Shareholders' equity increased to $14.2B from $10.8B, reflecting net income growth partially offset by dividends and buybacks.
Investment Risks & Concerns
Risk Factor
Intense competition from multinational pharmaceutical, biotechnology, and generic/biosimilar manufacturers could materially adversely affect the business.
Risk Factor
Increasing government price controls and other public/private restrictions on pricing, reimbursement, and access could materially affect results.
Risk Factor
Pharmaceutical R&D is very costly and highly uncertain; failure to replenish the pipeline could materially affect the business.
Risk Factor
Loss of effective intellectual property protection for key products has resulted and will likely continue to result in rapid and severe revenue declines.
Risk Factor
Manufacturing, quality, or supply chain difficulties could lead to product supply problems.
Management Strategy & Execution
Themes
- Revenue growth driven by incretin products (Mounjaro, Zepbound) and Verzenio, with Trulicity declining due to competitive pressures.
- Significant investment in manufacturing capacity to meet demand for incretin medicines; capex expected to remain elevated.
- Pipeline progress with approximately 55 new medicine candidates in clinical development, including tirzepatide for multiple indications.
- Impact of IRA: Jardiance selected for government-set pricing in 2026 at a 66% discount; additional products expected to be selected in future years.
Capital allocation
- Capital expenditures of $5.1B in 2024, up from $3.4B in 2023, focused on manufacturing capacity expansion.
- Dividends paid of $4.7B ($5.20 per share); quarterly dividend increased to $1.50 per share for Q1 2025.
- Share repurchases of $2.5B in 2024, completing the $5.0B program; new $15.0B program authorized in December 2024.
- Acquired IPR&D spending of $3.3B, primarily for Morphic acquisition.
“Revenue increased in 2024 driven by increased volume and, to a lesser extent, higher realized prices.”
— Management
“We are making investments in global facilities to manufacture existing and future products. These investments... will result in meaningfully higher capital expenditures over the next several years.”
— Management
Business Segment Analysis
| Segment | Revenue | Change | Commentary |
|---|---|---|---|
| Cardiometabolic Health | $29.5B | +50% | Driven by Mounjaro (+124% to $11.5B) and Zepbound ($4.9B, launched Nov 2023). Trulicity declined 26% to $5.3B. Jardiance revenue up 22% to $3.3B. |
| Oncology | $8.8B | +32% | Verzenio revenue up 37% to $5.3B, driven by increased demand and higher realized prices. Tyvyt revenue up 34% to $526M. |
| Immunology | $4.4B | +16% | Taltz revenue up 18% to $3.3B, driven by higher realized prices and increased demand. Olumiant revenue up 4% to $957M. |
| Neuroscience | $1.5B | -49% | Decline due to 2023 sale of olanzapine portfolio rights (Zyprexa revenue fell 93% to $116M). Emgality revenue up 28% to $870M. |
Liquidity & Capital Structure
Leverage: Total debt increased to $33.6B from $25.2B; debt-to-equity ratio rose to 2.4x from 2.3x.
Liquidity: Cash and equivalents of $3.3B; $8.45B in unused committed bank credit facilities, including $8.0B supporting commercial paper program.
Shareholder returns
- Dividends paid: $4.7B in 2024; indicated annual rate for 2025 of $6.00 per share.
- Share repurchases: $2.5B in 2024; new $15.0B program authorized in December 2024.
Forward Outlook & Investment Implications
Not disclosed—no specific quantitative guidance provided in the excerpts.
Drivers
- Continued demand growth for incretin products (Mounjaro, Zepbound) and pipeline progress.
- Manufacturing capacity expansion to support supply; additional capacity expected over next several years.
- Impact of IRA price setting on Jardiance starting 2026 and potential future products.
Watch items
- Trulicity patent expirations in the next few years.
- Regulatory and legislative actions on drug pricing, including IRA implementation.
- Supply chain and manufacturing execution risks.
Notable Footnotes
| Item | Impact |
|---|---|
| Acquired IPR&D charges of $3.28B in 2024, primarily from Morphic acquisition (Note 3). | Significant expense reducing operating income; reflects active business development strategy. |
| Litigation charge of $435.0M included in asset impairment, restructuring, and other special charges (Note 5). | Material one-time charge affecting net income. |
| Pre-launch inventory of $548.1M capitalized, primarily for orforglipron (Note 6). | Indicates confidence in upcoming product launch; risk of impairment if approval delayed. |
3-Year Investment Perspective
Revenue grew from $28.5B in 2022 to $45.0B in 2024 (CAGR ~25%), driven by new product launches (Mounjaro, Zepbound) and oncology growth. Net income rebounded from $6.2B in 2022 to $10.6B in 2024 after a dip in 2023 due to higher acquired IPR&D charges.
Inflections
- 2023 net income declined 16% YoY to $5.2B due to $3.8B in acquired IPR&D charges, before doubling in 2024.
- Gross margin expanded from 76.8% in 2022 to 81.3% in 2024, reflecting favorable product mix shift toward higher-margin incretin products.
- Operating cash flow dipped to $4.2B in 2023 from $7.6B in 2022, then surged to $8.8B in 2024.
Prior-period comparison
- 2022 revenue of $28.5B included $2.0B from COVID-19 antibodies, which had no sales in 2023 or 2024.
- 2022 net income of $6.2B was higher than 2023's $5.2B due to lower acquired IPR&D charges ($908M vs. $3.8B).
Ask LLY’s 10-K anything
Get plain-English answers, each cited to the exact filing text. Try a starter question:
AI-generated. Informational only, not investment advice. May be incomplete or contain errors. The authoritative source is always the original SEC filing.